Literature DB >> 18182247

Prostaglandin-induced VASP phosphorylation controls alpha II-spectrin breakdown in apoptotic cells.

Peter M Benz1, Stephan M Feller, Albert Sickmann, Ulrich Walter, Thomas Renné.   

Abstract

In pathological conditions, the inflammatory mediator prostaglandin E2 (PGE2) has been shown to induce apoptosis through a cAMP-dependent pathway. However, underlying mechanisms have remained illusive. Irrespective whether apoptosis is induced by the intrinsic or extrinsic pathway, the cysteine protease caspase-3 becomes activated and cleaves many key proteins including spectrins. Cleavage of the plasma membrane-associated spectrins leads to cell shrinkage, membrane blebbing, the formation of apoptotic bodies, and irreversible cell death. Recently, we identified a novel interaction between alpha II-spectrin and vasodilator-stimulated phosphoprotein (VASP), which is abrogated by the cAMP-dependent protein kinase (PKA)-mediated phosphorylation of VASP. In the present study we investigated whether VASP binding to alpha II-spectrin affects spectrin breakdown in PGE2-induced apoptosis. PGE2 dose- and time-dependently triggered VASP phosphorylation. Following induction of apoptosis, caspase-3-mediated alpha II-spectrin breakdown and membrane blebbing were markedly delayed in wild-type as compared to VASP-deficient endothelial cells. This suggests that VASP binding to alpha II-spectrin attenuates alpha II-spectrin cleavage in apoptotic cells and that PGE2-induced VASP phosphorylation regulates this process. Our findings may therefore provide the molecular basis for PGE2-induced apoptosis in pathological events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18182247     DOI: 10.1016/j.intimp.2007.10.004

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  EP4 and EP2 receptor activation of protein kinase A by prostaglandin E2 impairs macrophage phagocytosis of Clostridium sordellii.

Authors:  Lisa M Rogers; Tennille Thelen; Krystle Fordyce; Emilie Bourdonnay; Casey Lewis; Han Yu; Junyong Zhang; Jingli Xie; Carlos H Serezani; Marc Peters-Golden; David M Aronoff
Journal:  Am J Reprod Immunol       Date:  2013-08-01       Impact factor: 3.886

2.  A Role for cAMP and Protein Kinase A in Experimental Necrotizing Enterocolitis.

Authors:  Brian P Blackwood; Douglas R Wood; Carrie Yuan; Joseph Nicolas; Isabelle G De Plaen; Kathryn N Farrow; Pauline Chou; Jerrold R Turner; Catherine J Hunter
Journal:  Am J Pathol       Date:  2016-12-08       Impact factor: 4.307

Review 3.  Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger.

Authors:  P A Insel; L Zhang; F Murray; H Yokouchi; A C Zambon
Journal:  Acta Physiol (Oxf)       Date:  2011-05-26       Impact factor: 6.311

4.  Protein kinase A activation by the anti-cancer drugs ABT-737 and thymoquinone is caspase-3-dependent and correlates with platelet inhibition and apoptosis.

Authors:  Natalia Rukoyatkina; Elke Butt; Hariharan Subramanian; Viacheslav O Nikolaev; Igor Mindukshev; Ulrich Walter; Stepan Gambaryan; Peter M Benz
Journal:  Cell Death Dis       Date:  2017-06-29       Impact factor: 8.469

5.  VASP regulates leukocyte infiltration, polarization, and vascular repair after ischemia.

Authors:  Hebatullah Laban; Andreas Weigert; Joana Zink; Amro Elgheznawy; Christoph Schürmann; Lea Günther; Randa Abdel Malik; Sabrina Bothur; Susanne Wingert; Rolf Bremer; Michael A Rieger; Bernhard Brüne; Ralf P Brandes; Ingrid Fleming; Peter M Benz
Journal:  J Cell Biol       Date:  2018-03-05       Impact factor: 10.539

Review 6.  The Role of Nonerythroid Spectrin αII in Cancer.

Authors:  Anne Ackermann; Angela Brieger
Journal:  J Oncol       Date:  2019-05-02       Impact factor: 4.375

7.  Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells.

Authors:  Gen-Lin He; Zhen Luo; Ju Yang; Ting-Ting Shen; Yi Chen; Xue-Sen Yang
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.